Hexen is an analgesic of the opioid family first developed by Upjohn some 40 years ago. It was derived form a related opioid, AH-7921. Despite its importance in developing this class of opioid chemicals, hexen has never itself been formally tested on humans or animals.
hexen is highly selective for the µ-opioid receptor, and is believed to be roughly 7 to 8 times as powerful as morphine dose-per-dose. It is believed to be a strong kappa agonist, so should not produce substantial degrees of dysphoria or other unwanted effects.